Page 4 - Demo

Foreword
With gene therapy continuing to capture the the imagination and hopes of people across the world is pressing forward with its transformative science and unwavering confidence in in the future of In 2020 the the industry pipeline for cell and gene therapies expanded to 378 agents Published estimates indicate that there could be 30–60 approved cell and gene therapies by 2035 delivering revolutionary treatment to 350 000 US patients is responsible for effectively articulating the value proposition of taking into account the novel attributes of gene therapies addressing market access and payer payer affordability and ensuring data is relevant ffor for payer payer decision-making In addition given the higher upfront costs relative to traditional biopharmaceuticals is leading the creation of innovative reimbursement solutions as as well as as leading the way to institute new value assessment frameworks Despite the global pandemic of 2020 this year saw major advancements in s s s s s efforts to address the myriad requirements necessary for for preparing for for health economics and and outcomes research market access and and reimbursement This report shares the ongoing and new initiatives prioritized in in 2020 Building on the achievements of this last year our work in in 2021 will continue to pioneer new evidence for the launch- readiness of 4 CONFIDENTIAL